Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 2(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04343287Phase 2Completed

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Role: lead

NCT03066219Phase 2Completed

Safety and Efficacy of BRM421 for Dry Eye Syndrome

Role: lead

NCT07422389Unknown

BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

Role: lead

NCT07078955Phase 2Not Yet Recruiting

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Role: lead

NCT05927428Phase 2Recruiting

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Role: lead

NCT05695781Phase 3Completed

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

Role: lead

All 6 trials loaded